{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:55:18Z","timestamp":1761738918660,"version":"build-2065373602"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The treatment of positive margins following primary resection of cutaneous melanoma remains controversial with the current standard of care being repeat surgical resection. 5% topical imiquimod therapy has been proposed as an alternative treatment for positive\n                      <jats:italic>in-situ<\/jats:italic>\n                      surgical margins. This study revisits the use of 5% topical imiquimod therapy as a method of clearing positive surgical margins following primary excision of cutaneous melanoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective chart review of all Yale Melanoma Registry Database patients with positive melanoma\n                      <jats:italic>in situ<\/jats:italic>\n                      margins after excision of primary melanoma between January 2008 and December 2021 was conducted. Patients were included if they received 5% topical imiquimod therapy for treatment of positive melanoma\n                      <jats:italic>in situ<\/jats:italic>\n                      surgical margins. Demographics, treatment duration, treatment response, complications, follow-up time, and associated costs were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 69 patients with positive margins post wide local excisions were treated with topical imiquimod therapy. 38 of these patients had histological diagnosis of melanoma at primary excision while the remainder, 31, had MIS. Five patients were excluded due to follow-up with an outside dermatologist, leaving 64 patients in the final cohort. Fifty-two percent of patients were female with a median age of 73 years old in the entire cohort of patients. Treatment duration with imiquimod ranged from four to twelve weeks of therapy with a median duration of 12 weeks. Clinical response rate after final biopsies was 84% over an average follow-up duration of 36 months. Six patients (8.7%) had recurrences in follow-up after negative scouting biopsies following treatment with an average follow-up duration of 1086 days or approximately 36 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of 5% topical imiquimod therapy is a safe, cost-effective, and reasonable alternative approach in the management of positive surgical margins. The degree of inflammation around the site of disease may be used as a reliable predictor of outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1666463","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:09Z","timestamp":1761715869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of imiquimod topical therapy for management of malignant melanoma positive margins"],"prefix":"10.3389","volume":"15","author":[{"given":"Katelyn","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Alper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Carney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Ariyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Olino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Clune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27250","article-title":"Immediate versus delayed reconstruction of head and neck cutaneous melanoma","volume":"128","author":"Quimby","year":"2018","journal-title":"Laryngoscope"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1378","DOI":"10.1097\/gox.0000000000001378","article-title":"Recurrence rates over 20 years in the treatment of Malignant melanoma: immediate versus delayed reconstruction","volume":"5","author":"Koolen","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2016-0031","article-title":"A surgical perspective report on melanoma management","volume":"4","author":"Wernick","year":"2017","journal-title":"Melanoma Manage"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/prs.0000000000002241","article-title":"Melanoma extirpation with immediate reconstruction: the oncologic safety and cost savings of single-stage treatment","volume":"138","author":"Karanetz","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN guidelines\u00ae Insights: melanoma: cutaneous, version 2.2021","volume":"19","author":"Swetter","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/sap.0000000000000949","article-title":"Treatment of head and neck melanoma in situ with staged contoured marginal excisions","volume":"78","author":"Glazer","year":"2017","journal-title":"Ann Plast Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1097\/gox.0000000000002661","article-title":"Impact of immediate surgical reconstruction following wide local excision of Malignant head and neck melanoma","volume":"8","author":"Hu","year":"2020","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.065","article-title":"Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy","volume":"74","author":"Bolshinsky","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0194599820969178","article-title":"Positive margins in cutaneous melanoma of the head and neck: implications for timing of reconstruction","volume":"164","author":"Namin","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.05.094","article-title":"Residual melanoma in wide local excision specimens after \u2018complete\u2019 excision of primary cutaneous in situ and invasive melanomas","volume":"54","author":"Jackett","year":"2022","journal-title":"Pathology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","article-title":"Age-specific incidence of melanoma in the United States","volume":"156","author":"Paulson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.402","article-title":"Using topical imiquimod for the management of positive in situ margins after melanoma resection","volume":"4","author":"Pandit","year":"2015","journal-title":"Cancer Med"},{"key":"B14","unstructured":"Clinical practice guidelines in oncology: melanoma. v3.2022"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00174.x","article-title":"Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463","volume":"110","author":"Imbertson","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2012.02362.x","article-title":"Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature","volume":"38","author":"Ellis","year":"2012","journal-title":"Dermatol Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107954","article-title":"Topical imiquimod treatment of a cutaneous melanoma metastasis","volume":"43","author":"Steinmann","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1046\/j.0366-077x.2003.05637.x","article-title":"Treatment of lentigo Maligna with topical imiquimod","author":"Naylor","year":"2003","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.260","article-title":"Efficacy of imiquimod cream, 5%, for lentigo Maligna after complete excision: a study of 43 patients","volume":"147","author":"Ly","year":"2011","journal-title":"Arch Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000073101","article-title":"Topical treatment of lentigo Maligna melanoma with imiquimod 5% cream","volume":"207","author":"Borucki","year":"2003","journal-title":"Dermatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical treatment of cutaneous metastases of Malignant melanoma using combined imiquimod and 5-fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Invest New Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13053","article-title":"Lentigo Maligna successfully treated with combination therapy of topical tazarotene and imiquimod","volume":"42","author":"Menzies","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00473-w","article-title":"Treating melanoma in situ during a pandemic with telemedicine and a combination of imiquimod, 5-fluorouracil, and tretinoin","volume":"11","author":"Nahm","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo Maligna, followed by conservative staged excisions","volume":"148","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.060","article-title":"100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series","volume":"73","author":"Shi","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2022.2125266","article-title":"A case of topical imiquimod induced fatigue","author":"Raman","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-199301000-00014","article-title":"Data on first recurrence after treatment for Malignant melanoma in a large patient population","volume":"91","author":"Fusi","year":"1993","journal-title":"Plast Reconstr Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8813050","article-title":"Histological peripheral margins and recurrence of melanoma in situ treated with wide local excision","volume":"2020","author":"Moura","year":"2020","journal-title":"J Skin Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1666463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:11Z","timestamp":1761715871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1666463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1666463"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1666463","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1666463"}}